tiprankstipranks
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
US Market

Silexion Therapeutics (SLXN) Income Statement

Compare
105 Followers

Silexion Therapeutics Income Statement

Last quarter (Q3 2024), Silexion Therapeutics's total revenue was $0.00, a decrease of ― from previous quarter. In Q3, Silexion Therapeutics's net income was $-11.85M. See Silexion Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22
Total Revenue
$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00
Operating Expenses
$ 4.68M$ 3.86M
Depreciation and Amortization
$ 45.00K$ 57.00K
EBITDA
$ -4.64M$ -3.80M
Operating Income
$ -4.68M$ -3.86M
Other Income/Expenses
$ -395.00K$ 396.00K
Pretax Income
$ -5.08M$ -3.46M
Net Income
$ -4.94M$ -3.21M
Per Share Metrics
$ ―$ ―
Basic EPS
$ -0.61$ -0.39
Diluted EPS
$ -0.61$ -0.39
Weighted Average Shares Outstanding
8.15M 8.15M
Weighted Average Shares Outstanding (Diluted)
8.15M 8.15M
Currency in USD

Silexion Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis